Infections caused by carbapenem-resistant Enterobacterales (CRE) present an important therapeutic problem, as there are limited number of effective therapeutic alternatives available. In this study, phenotypic and genotypic methods were used to characterize carbapenemase-production and other resistance-determinants (AmpC and ESBL-production, efflux pump-overexpression) in 50 isolates (Klebsiella spp. n = 35, Escherichia coli n = 12 and Enterobacter cloacae complex n = 3) collected at the Albert Szent-Györgyi Clinical Center (University of Szeged) between 2014 and 2017. Minimum inhibitory concentrations of meropenem, sulfamethoxazole/trimethoprim, tigecycline, amikacin, moxifloxacin, colistin and fosfomycin were also determined. 24% of isolates were AmpC-producers, while 30% carried blaCTX-M ESBL-genes. Carbapenemase-genes were detected in 18 (36%) of the tested isolates in 2 isolates blaNDM, in 6 isolates blaOXA-48-like and in 12 isolates, blaVIM was detected by PCR. The species-distribution for isolates positive for carbapenemase-genes was the following Klebsiella pneumoniae n = 11, Klebsiella oxytoca n = 1, E. coli n = 5, E. cloacae complex n = 1. Efflux pump-overexpression based on the PAβN-screening agar was shown in n = 3 of the tested strains. In nine isolates (18%), carbapenemase and ESBL-genes were detected simultaneously. Highest levels of resistance were noted for fosfomycin (74%) and moxifloxacin (70%), while all isolates were susceptible to colistin. Among applied phenotypic tests in this study the modified carbapenem inactivation method (mCIM) proved to be the most accurate one compared to that of PCR results.Some studies suggested an association between Helicobacter pylori infection and iron-deficiency anemia, however, the link between weight loss and the infection in childhood remains non-established. In a retrospective cohort study, we compared H. pylori positivity rates of Bulgarian children without or with anemia (47 children in each group) or weight loss (45 children in each group) and both conditions (17 children in each group). H. https://www.selleckchem.com/products/su6656.html pylori infection was associated with the presence of anemia (in 76.6% of the anemic vs. 21.3% of the non-anemic patients, P less then 0.0001) and weight loss (in 82.2% of the patients vs. 17.8% of the control children, P less then 0.0001). All 17 patients with both conditions were H. pylori positive. Relative risk of anemia, weight loss and both conditions was 3.6 (95% CI, 2.0-6.4), 4.6 (95% CI, 2.4-8.8) and 5.7 (95% CI, 2.0-15.8), respectively, in the children with H. pylori infection. In conclusion, H. pylori infection was significantly associated with iron-deficiency anemia or/and weight loss in Bulgarian pediatric patients. Therefore, diagnostics and treatment of the infection as well as a proper control of the eradication success can be beneficial and thus, can be recommended for children with those conditions.Daily and on-demand pre-exposure prophylaxis (PrEP) has been well demonstrated to effectively prevent HIV acquisition for men who have sex with men (MSM). More than half of the MSM PrEP users in Taiwan prefer on-demand PrEP; however, on-demand PrEP involves a complicated dosing regimen because it requires precoital and postcoital dosing and sex events are hard to anticipate. Although there are a growing number of mobile apps designed to improve access to HIV prevention services and HIV medication adherence, few mobile apps focus on adherence to PrEP or are designed to accommodate a complicated, on-demand PrEP dosing schedule.
The aim of this project is to evaluate the usability of a newly developed mobile app (UPrEPU) to assist MSM PrEP users to self-monitor their adherence to either daily or on-demand PrEP using a user-centered scheme.
This research will be conducted in 2 phases app development and usability study. In the app development phase, we will first conduct formative research with end users an.
Refinement of the UPrEPU app is currently ongoing. The usability study commenced in May 2020.
The UPrEPU app is one of the first apps designed to help MSM PrEP users to self-manage their PrEP schedule better regardless of dosing modes. With a design-thinking approach and adapting to the cultural context in Taiwan's MSM population, this novel app will have substantial potential to be acceptable and feasible and contribute to the reduction of new HIV infections.
ClinicalTrials.gov NCT04248790; https//clinicaltrials.gov/ct2/show/NCT04248790.
PRR1-10.2196/20360.
PRR1-10.2196/20360.Negative symptoms are an important unmet treatment need for schizophrenia. This study is a preliminary, open, single-arm trial of a novel hybrid intervention called mobile-assisted cognitive behavioral therapy for negative symptoms (mCBTn).
The primary aim was to test whether mCBTn was feasible and could reduce severity of the target mechanism, defeatist performance attitudes, which are associated with experiential negative symptoms and poor functioning in schizophrenia.
Participants with schizophrenia or schizoaffective disorder (N=31) who met prospective criteria for persistent negative symptoms were enrolled. The blended intervention combines weekly in-person group therapy with a smartphone app called CBT2go. The app extended therapy group skills, including recovery goal setting, thought challenging, scheduling of pleasurable activities and social interactions, and pleasure-savoring interventions to modify defeatist attitudes and improve experiential negative symptoms.
Retention was excellent (87% at 18 weeks), and severity of defeatist attitudes and experiential negative symptoms declined significantly in the mCBTn intervention with large effect sizes.
The findings suggest that mCBTn is a feasible and potentially effective treatment for experiential negative symptoms, if confirmed in a larger randomized controlled trial. The findings also provide support for the defeatist attitude model of experiential negative symptoms and suggest that blended technology-supported interventions such as mCBTn can strengthen and shorten intensive psychosocial interventions for schizophrenia.
ClinicalTrials.gov NCT03179696; https//clinicaltrials.gov/ct2/show/NCT03179696.
ClinicalTrials.gov NCT03179696; https//clinicaltrials.gov/ct2/show/NCT03179696.